Shares of Dendreon Corp. moved higher Monday after the company said sales of its prostate cancer therapy Provenge continued to grow in the fourth quarter. Provenge sales totaled $81.6 million, excluding special items. That's an improvement of 5 percent from the third quarter, and up 51 percent...
WASHINGTON (AP) — Shares of biotech developer Dendreon Corp. rose Friday after health insurer Aetna said it would expand coverage of Provenge, the company's pricey prostate cancer drug.
NEW YORK (AP) — Shares of Dendreon Corp. slumped Monday after Johnson & Johnson reported positive clinical data for a prostate cancer drug that competes with Dendreon's therapy Provenge.
NEW YORK (AP) — Shares of Dendreon Corp. sank Wednesday after a Jefferies & Co. analyst said the company's prostate cancer therapy Provenge will be eclipsed by two newer competitors.
WASHINGTON (AP) — Shares of biotech drugmaker Dendreon fell today on worries about an investigation into company conduct by financial regulators.
Dendreon tumbled more than 12 percent in premarket trading Tuesday after the drug developer reported a loss and what an analyst described as "modest growth" for the company's only marketed product, the prostate cancer treatment Provenge.
Dendreon said Tuesday that it sold its royalty interest in Merck & Co.’s hepatitis C drug Victrelis (boceprevir) for $125 million in a move that is expected to strengthen the company’s cash holdings.
SEATTLE (AP) — Dendreon Corp. said Thursday that it will eliminate 500 jobs, or more than a quarter of its work force, as it reduces costs to compensate for disappointing sales of its prostate cancer therapy Provenge.